Board of Directors
Corporate Management
R&D Management
The Market
Our Beginnings
TauRx Group Fact Sheet
|
R&D Management
Strategy
| Hans Moebius, PhD, MD. Chief Medical Officer |
|
 | |
Dr. Moebius is board certified in neurology and psychiatry, with 20 years of pharmaceutical drug development experience and strong R&D operational skills gained in Europe, the USA and Japan. Dr. Moebius led the clinical development and regulatory strategy supporting the launch of Memantine, Merz’s blockbuster therapy for the treatment of Alzheimer’s disease symptoms. He has overseen the development of drugs for epilepsy, Parkinson's Disease, depression, Alzheimer's disease, vascular dementia, ADHD, spasticity, neuropathic pain, chronic pain, and addiction. He has interacted with the FDA, EMA and several national authorities for the successful registration of five new CNS therapies, being responsible for all aspects of pre-clinical and clinical development, regulatory strategy and for establishing global pharmacovigilance strategies. Dr. Moebius joined TauRx in 2009. |
| Karin Kook, PhD. Lead Consultant for Regulatory Affairs and Strategy |
|
 | |
Dr. Kook is trained in clinical pharmacology and Managing Director of Salamandra LLC and provides regulatory and preclinical management support for TauRx’s development and regulatory program. Dr. Kook has extensive experience in the design, development and execution of regulatory strategies as well as operations. Primary areas of technical expertise are in the clinical and regulatory aspects of product development, gained over the past 23 years working at the FDA, the pharmaceutical industry and consulting. |
Operations
| Charles Harrington, PhD. Deputy Chief Scientific Officer |
|
| Dr. Harrington is responsible for TauRx’s biological research activities and intellectual property. Dr Harrington has extensive research experience in the field of neurodegenerative diseases and in particular Alzheimer’s disease, and is an author of more than 50 publications and co-inventor of 8 patent applications either granted or pending in the field. He has collaborated with Professor Wischik for over 20 years, currently as a member of the management team, previously while at the Cambridge Brain Bank Laboratory (fellowships from the Medical Research Council, ICI Ltd. and the Newton Trust, Trinity College) and later as a Senior Research Fellow in the Institute of Medical Sciences at the University of Aberdeen. During this period, Prof. Wischik, Dr. Harrington and colleagues developed assays for screening agents having the potential to prevent the Tau pathology that is a hallmark of Alzheimer’s disease, which they built upon to create the platform technology at TauRx, one on the most sophisticated and extensive Tau directed platforms currently available. Previously, Dr. Harrington was an R&D programme manager at Murex Medical Research Ltd, Cambridge. Dr. Harrington received his PhD in Microbiology from Glasgow University, was an NIH Fellow in Kansas City, Missouri and was a fellow in Professor Sir James Baddiley’s lab in the Department of Biochemistry at the University of Cambridge. |
| John Storey, Ph.D. Head Chemist |
|
| Professor Storey and his team have synthesized TauRx’s portfolio of drug candidates. He is responsible for their chemical scale-up, analysis, encapsulation and formulation and is responsible for relationships with external contract manufacturers. He also manages the TauRx GLP test facility, situated at the University of Aberdeen, which is the only University-based facility in the UK that is both GLP and GCP compliant. Professor Storey also holds the position of Chair of Pharmaceutical Industrial Chemistry at Aberdeen University from which he has collaborated with TauRx for 8 Years. He was previously senior lecturer in pharmaceutical science at Kingston University. Professor Storey ’s primary research interests are free radical chemistry, organic methodology and medicinal chemistry. Professor Storey has published chapters in mechanistic organic chemistry books and reviews on radical chemistry and individual publications in the area of chemical synthesis and radical chemistry. Professor Storey is a co-inventor of 10 patents pending with TauRx. Professor Storey received his Ph.D. at Kings College London then went on to work with Prof. Athelstan Beckwith FRS and Prof. Lewis Mander FRS at the Australian National University, Canberra. |
| Diane Downie, Ph.D. Clinical Project Manager |
|
| Dr. Downie was promoted to her current position in 2006 having joined TauRx as a clinical research associate in 2004. She is responsible for the day to day management of clinical trials to include liasons with external contractors, international coordination of clinical trial set-up and management of patient data for clinical analysis. Prior to joining TauRx, Dr. Downie was a postdoctorate research associate studying Cytochrome P450 pathways in ovarian cancer after obtaining her Ph.D. at Aberdeen University in 2002. Dr. Downie is a Professional Member of the Institute of Clinical Research. |
| John K S Cheung, Ph.D. Non-Clinical Development Manager |
|
| Dr. Cheung joined TauRx Therapeutics Ltd in 2004 and is responsible for the coordination and oversight of non-clinical development, which consists of toxicology, safety pharmacology and DMPK. Responsibilities include review and maintenance of contractual arrangements; study protocol and report review; liaising with key members of the TauRx Development Team and overall management of non-clinical CROs. He has provided support to other functions within the company including pharmaceutical development, regulatory affairs, clinical trial finance control and CMC. Dr. Cheung received his Ph.D. in Medicine and Therapeutics from the University of Aberdeen. |
|